{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:01:26Z","timestamp":1791302486060,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:00:00Z","timestamp":1716076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.intimp.2024.112273","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T23:06:37Z","timestamp":1716851197000},"page":"112273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells"],"prefix":"10.1016","volume":"136","author":[{"given":"Chutipa","family":"Chiawpanit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3949-9887","authenticated-orcid":false,"given":"Methi","family":"Wathikthinnakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-9948","authenticated-orcid":false,"given":"Nunghathai","family":"Sawasdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaporn","family":"Phanthaphol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-8031","authenticated-orcid":false,"given":"Jatuporn","family":"Sujjitjoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-3000","authenticated-orcid":false,"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montarop","family":"Yamabhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutatip","family":"Panaampon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-1881","authenticated-orcid":false,"given":"Aussara","family":"Panya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11894-017-0542-4","article-title":"Update on the diagnosis and treatment of cholangiocarcinoma","volume":"19","author":"Doherty","year":"2017","journal-title":"Curr. Gastroenterol. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2024.112273_b0010","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jhep.2006.09.001","article-title":"Cholangiocarcinoma: modern advances in understanding a deadly old disease","volume":"45","author":"Malhi","year":"2006","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.intimp.2024.112273_b0020","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2024.112273_b0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.intimp.2024.112273_b0030","article-title":"Cholangiocarcinoma in the era of immunotherapy","volume":"11","author":"Manthopoulou","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"S1","key":"10.1016\/j.intimp.2024.112273_b0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2024.112273_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.intimp.2024.112273_b0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.intimp.2024.112273_b0055","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10254","key":"10.1016\/j.intimp.2024.112273_b0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.intimp.2024.112273_b0065","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2024.112273_b0070","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112273_b0075","first-page":"e14494","article-title":"A systematic review of the role of chimeric antigen receptor T (CAR-T) cell therapy in the treatment of solid tumors","volume":"13","author":"Siddiqui","year":"2021","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.intimp.2024.112273_b0080","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3892\/etm.2021.9771","article-title":"Chimeric antigen receptor-natural killer cells: novel insight into immunotherapy for solid tumors (review)","volume":"21","author":"Peng","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.112273_b0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2021.04.029","article-title":"Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer","volume":"512","author":"Mori","year":"2021","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.intimp.2024.112273_b0095","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138928","article-title":"Role of c-Met\/\u03b21 integrin complex in the metastatic cascade in breast cancer","volume":"6","author":"Lau","year":"2021","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.intimp.2024.112273_b0100","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1002\/jcp.26232","article-title":"Clinical and prognostic value of the C-Met\/HGF signaling pathway in cervical cancer","volume":"233","author":"Boromand","year":"2018","journal-title":"J. Cell Physiol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112273_b0105","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/jcp.25794","article-title":"C-Met as a potential target for the treatment of gastrointestinal cancer: current status and future perspectives","volume":"232","author":"Bahrami","year":"2017","journal-title":"J. Cell Physiol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112273_b0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41419-019-1460-1","article-title":"Targeting c-MET by Tivantinib through synergistic activation of JNK\/c-jun pathway in cholangiocarcinoma","volume":"10","author":"Wei","year":"2019","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.intimp.2024.112273_b0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1533034615578959","article-title":"Prognostic value of c-met expression in cholangiocarcinoma","volume":"15","author":"Mao","year":"2016","journal-title":"Technol. Cancer Res. Treat"},{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0120","doi-asserted-by":"crossref","first-page":"25369","DOI":"10.1038\/srep25369","article-title":"Expression levels of ROS1\/ALK\/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer","volume":"6","author":"Chiang","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/bjc.2011.199","article-title":"Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma","volume":"105","author":"Miyamoto","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.112273_b0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10408363.2019.1653821","article-title":"HGF\/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers","volume":"56","author":"Moosavi","year":"2019","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.intimp.2024.112273_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106656","article-title":"Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma","volume":"188","author":"Peng","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2024.112273_b0140","first-page":"2823","article-title":"Development of c-MET-specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells","volume":"20","author":"Liu","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2024.112273_b0145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6750-9-6","article-title":"A compact phage display human scFv library for selection of antibodies to a wide variety of antigens","volume":"9","author":"Pansri","year":"2009","journal-title":"BMC Biotechnol."},{"issue":"W1","key":"10.1016\/j.intimp.2024.112273_b0150","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.intimp.2024.112273_b0155","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/bioinformatics\/btu097","article-title":"ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers","volume":"30","author":"Pierce","year":"2014","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.intimp.2024.112273_b0160","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/ja026939x","article-title":"HADDOCK: a protein\u2212protein docking approach based on biochemical or biophysical information","volume":"125","author":"Dominguez","year":"2003","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.intimp.2024.112273_b0165","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother"},{"issue":"5","key":"10.1016\/j.intimp.2024.112273_b0170","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","article-title":"Engineering the next generation of CAR-NK immunotherapies","volume":"114","author":"Biederst\u00e4dt","year":"2021","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112273_b0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy","volume":"18","author":"Comoglio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2024.112273_b0180","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13577-020-00334-w","article-title":"Functional and genetic characterization of three cell lines derived from a single tumor of an opisthorchis viverrini-associated cholangiocarcinoma patient","volume":"33","author":"Sripa","year":"2020","journal-title":"Hum. Cell"},{"issue":"18","key":"10.1016\/j.intimp.2024.112273_b0185","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3748\/wjg.v11.i18.2748","article-title":"Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines","volume":"11","author":"Tepsiri","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/1878-0261.12017","article-title":"Epithelial-mesenchymal transition in tumor metastasis","volume":"11","author":"Yeung","year":"2017","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0195","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jss.2006.05.031","article-title":"Involvement of c-Met\/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met","volume":"136","author":"Leelawat","year":"2006","journal-title":"J. Surg. Res."},{"issue":"19","key":"10.1016\/j.intimp.2024.112273_b0200","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.3748\/wjg.14.2990","article-title":"c-Met targeted therapy of cholangiocarcinoma","volume":"14","author":"Socoteanu","year":"2008","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112273_b0205","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/mc.22449","article-title":"Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma","volume":"55","author":"Barat","year":"2016","journal-title":"Mol. Carcinog."},{"issue":"2","key":"10.1016\/j.intimp.2024.112273_b0210","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma\u2014evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112273_b0215","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdu157","article-title":"A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors","volume":"25","author":"Pant","year":"2014","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112273_b0220","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2024.112273_b0225","doi-asserted-by":"crossref","first-page":"19109","DOI":"10.3390\/ijms140919109","article-title":"Single-chain fragment variable passive immunotherapies for neurodegenerative diseases","volume":"14","author":"Huang","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2024.112273_b0230","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/19420862.2016.1277302","article-title":"A strategy to identify linker-based modules for the allosteric regulation of antibody-antigen binding affinities of different scFvs","volume":"9","author":"Kellmann","year":"2017","journal-title":"MAbs"},{"issue":"12","key":"10.1016\/j.intimp.2024.112273_b0235","doi-asserted-by":"crossref","first-page":"e0189964","DOI":"10.1371\/journal.pone.0189964","article-title":"Complementarity determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv","volume":"12","author":"G\u0105ciarz","year":"2017","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.intimp.2024.112273_b0240","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4\u20131BB)","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.intimp.2024.112273_b0245","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1158\/1078-0432.CCR-12-0319","article-title":"Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells","volume":"18","author":"Kong","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.112273_b0250","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10616-021-00476-1","article-title":"An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16\/CAR","volume":"73","author":"Zhao","year":"2021","journal-title":"Cytotechnology"},{"issue":"2","key":"10.1016\/j.intimp.2024.112273_b0255","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem. Cell"},{"issue":"8","key":"10.1016\/j.intimp.2024.112273_b0260","article-title":"Panya A: genistein sensitizes human cholangiocarcinoma cell lines to be susceptible to natural killer cells","volume":"11","author":"Chiawpanit","year":"2022","journal-title":"Biology (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0265","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-022-09964-6","article-title":"Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells","volume":"12","author":"Wathikthinnakon","year":"2022","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2024.112273_b0270","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.112273_b0275","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","article-title":"Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy","volume":"79","author":"Duan","year":"2021","journal-title":"Cell Mol. Life Sci."},{"issue":"17","key":"10.1016\/j.intimp.2024.112273_b0280","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor t cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:38:08Z","timestamp":1791301088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924007938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":56,"alternative-id":["S1567576924007938"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112273","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112273"}}